Literature DB >> 498598

Immunological and biochemical profiles in response to transfusion therapy in an adenosine deaminase-deficient patient with severe combined immunodeficiency disease.

J W Dyminski, A Daoud, B C Lampkin, S Limouze, J Donofrio, M S Coleman, J J Hutton.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1979        PMID： 498598     DOI： 10.1016/0090-1229(79)90157-0

Source DB:  PubMed          Journal:  Clin Immunol Immunopathol        ISSN： 0090-1229


× No keyword cloud information.
  6 in total

1.  Pathologic findings in adenosine deaminase deficient-severe combined immunodeficiency. II. Thymus, spleen, lymph node, and gastrointestinal tract lymphoid tissue alterations.

Authors:  H Ratech; R Hirschhorn; M A Greco
Journal:  Am J Pathol       Date:  1989-12       Impact factor: 4.307

2.  Pathologic findings in adenosine deaminase-deficient severe combined immunodeficiency. I. Kidney, adrenal, and chondro-osseous tissue alterations.

Authors:  H Ratech; M A Greco; G Gallo; D L Rimoin; H Kamino; R Hirschhorn
Journal:  Am J Pathol       Date:  1985-07       Impact factor: 4.307

3.  Biochemical and functional abnormalities in lymphocytes from an adenosine deaminase-deficient patient during enzyme replacement therapy.

Authors:  J J Hutton; D A Wiginton; M S Coleman; S A Fuller; S Limouze; B C Lampkin
Journal:  J Clin Invest       Date:  1981-08       Impact factor: 14.808

4.  Correction of adenosine deaminase deficiency in cultured human T and B cells by retrovirus-mediated gene transfer.

Authors:  P W Kantoff; D B Kohn; H Mitsuya; D Armentano; M Sieberg; J A Zwiebel; M A Eglitis; J R McLachlin; D A Wiginton; J J Hutton
Journal:  Proc Natl Acad Sci U S A       Date:  1986-09       Impact factor: 11.205

5.  Heterozygous Mutation in Adenosine Deaminase Gene in a Patient With Severe Lymphopenia Following Corticosteroid Treatment of Autoimmune Hemolytic Anemia.

Authors:  Serena I Tripodi; Paola Corti; Silvia Giliani; Arnalda Lanfranchi; Andrea Biondi; Raffaele Badolato
Journal:  Front Pediatr       Date:  2018-10-01       Impact factor: 3.418

6.  Pegademase bovine (PEG-ADA) for the treatment of infants and children with severe combined immunodeficiency (SCID).

Authors:  Claire Booth; H Bobby Gaspar
Journal:  Biologics       Date:  2009-07-13
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.